HC Wainwright Estimates Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – HC Wainwright issued their Q1 2027 EPS estimates for Envoy Medical in a report issued on Wednesday, July 15th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.19) EPS.

Envoy Medical (NASDAQ:COCH) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million.

COCH has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a research report on Friday, April 24th. Zacks Research raised Envoy Medical to a “hold” rating in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $2.50.

Envoy Medical Trading Down 7.7%

Shares of COCH opened at $0.70 on Thursday. Envoy Medical has a twelve month low of $0.36 and a twelve month high of $1.89. The firm has a market capitalization of $53.94 million, a P/E ratio of -0.69 and a beta of 1.88. The stock’s fifty day simple moving average is $0.69 and its 200 day simple moving average is $0.68.

Hedge Funds Weigh In On Envoy Medical

A number of hedge funds have recently made changes to their positions in COCH. Geode Capital Management LLC lifted its holdings in shares of Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock valued at $65,000 after acquiring an additional 51,813 shares in the last quarter. Focus Partners Wealth acquired a new stake in Envoy Medical in the 1st quarter valued at $276,000. CIBC Bancorp USA Inc. acquired a new stake in Envoy Medical in the 3rd quarter valued at $60,000. Finally, DSG Capital Advisors LLC purchased a new position in Envoy Medical in the first quarter valued at about $416,000. Hedge funds and other institutional investors own 8.59% of the company’s stock.

More Envoy Medical News

Here are the key news stories impacting Envoy Medical this week:

• Negative Sentiment: HC Wainwright lowered its Q2 2026 EPS estimate for Envoy Medical to ($0.09) from ($0.08) and cut its Q3 2026 EPS estimate to ($0.07) from ($0.06), signaling slightly weaker profitability expectations. Article link
• Neutral Sentiment: The firm still kept a Buy rating and $2.50 price target on COCH, suggesting analysts remain constructive on the longer-term story despite the near-term estimate cuts. Article link
• Neutral Sentiment: HC Wainwright also slightly improved its FY2026 EPS forecast to ($0.29) from ($0.30) and projected FY2027 EPS of ($0.19), indicating losses are expected to narrow over time. Article link

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.